טוען...

Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer

The PI3K/Akt/mTOR (phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin) pathway regulates several key cellular functions and its dysregulation creates an environment that promotes tumorigenesis as well as resistance to therapy. The mTOR inhibitor everolimus has emerged as a...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Saksena, Rujuta, Wong, Serena T
פורמט: Artigo
שפה:Inglês
יצא לאור: Dove Medical Press 2013
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3929343/
https://ncbi.nlm.nih.gov/pubmed/24648755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S30131
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!